TAG:
Mayo Clinic Laboratories
Strategies to Succeed with Laboratory Outreach Programs
By Stephen Beale | From the Volume XXXII, No. 18 – December 29, 2025 Issue
In recent years Labcorp and Quest Diagnostics went on buying sprees, acquiring laboratory outreach businesses from major health systems. They argue that they can run these operations more efficiently, while the sellers get much-needed cash infusions. (See …
Insights on Innovative Tech and Running a Clinical Lab in 2026
By Scott Wallask | From the Volume XXXII, No. 17 – December 8, 2025 Issue
CEO SUMMARY: William Morice II, MD, PhD, the CEO at Mayo Clinic Laboratories, discusses technology that intrigues him and the important steps clinical laboratory leaders can take to better steer revenue opportunities as they head into the new year. Morice also comments on …
At ADLM 2025, Spotlight Shines on Relationships
By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue
CEO SUMMARY: At the ADLM conference, a new industry survey about the dynamic relationship between medical laboratories, physicians, and patients presented a strong argument for labs taking the lead in communicating and being more accessible to their colleagues. A troubleso…
Hospital Lab Outreach: Still a Valuable Asset!
By Robert Michel | From the Volume XXXI, No. 13 – September 23, 2024 Issue
CEO SUMMARY: Hospital lab administrators everywhere are watching press releases announcing the latest agreement of a major health system selling its laboratory outreach business to one of the billion-dollar lab corporations. The pace of these sales is accelerating. These deals confirm the…
ACLA Files Court Challenge to FDA’s Final LDT Rule
By Robert Michel | From the Volume XXXI, No. 8 – June 10, 2024 Issue
CEO SUMMARY: Discussing the FDA’s final LDT rule, one pathologist tracking this matter wrote, “In many ways, the FDA’s plan [final LDT rule] is like the guy who gets three wishes from a genie, and he asks for unlimited wishes.” ACLA and HealthTrackRx are challenging the FDA’s …
Lab Data Crucial to Insurer Risk Adjustment Models
By Scott Wallask | From the Volume XXX, No. 13 – September 11, 2023 Issue
CEO SUMMARY: Payers who use risk adjustment models as part of Medicare Advantage need diagnostic data that helps them document ICD-10 diagnoses that earn them higher premium payments for sicker pat…
Six Important Themes to Help Labs Succeed
By Scott Wallask | From the Volume XXX, No. 5 – March 27, 2023 Issue
CEO SUMMARY: Clinical laboratories face business challenges with day-to-day operations, genetic testing, and evolving care delivery models. The 2023 Executive War College on Diagnostics, Clinical Laboratory, and Pathology Management returns on April 25-26 in New Orleans. Participant…
How Consumers Shape Modern Laboratory Outreach
By Robert Michel | From the Volume XXX, No. 1 – January 3, 2023 Issue
CEO SUMMARY: Each of the different generations engaging with clinical laboratory outreach programs brings their own set of expectations to a blood draw. Innovative hospital lab outreach programs should serve these differences by offering multiple options to provide appointment conve…
August 8, 2022 Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXIX, No. 11 – August 8, 2022 Issue
One of the biggest health insurers in the United States has changed its name. As of June 28, Anthem in Indianapolis, Ind., is now known as Elevance Health. The new name is a combination of “elevate” and “advance,” noted Modern Health Executive on June 16. Elevance also an…
July 18, 2022 Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXIX, No. 10 – July 18, 2022 Issue
Given that monkeypox cases continue to rise, the federal government likewise is ramping up its response. In June, the federal Centers for Disease Control and Prevention (CDC) began shipping monkeypox tests to five commercial laboratories: Aegis Science, Labcorp, Mayo Clinic La…
CURRENT ISSUE
Volume XXXIII, No. 1 – January 19, 2026
The Dark Report looks at the FDA’s move to reclassify Oncology companion diagnostics as Class II medical devices and considers how labs can benefit. Also, observers are concerned about the effect of PAMA cuts on rural clinical laboratories.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized